Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Genomics: Clinical Implementation » Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

Oct 12, 2018
|
staff reporter

NEW YORK (GenomeWeb) – New data this week has added evidence for the value of blood-based cancer testing in non-small cell lung cancer, demonstrating in a cohort of about 300 that comprehensive liquid biopsy — in this case Guardant Health's Guardant360 test — can help identify targeted mutations in more patients than tissue sequencing.

The study also found that patients treated on the basis of blood-based test results respond to treatment similarly to those treated based on tissue test results.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Move Away From Basic Research?

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Noel Rose Dies

Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.

Flush the System

According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.

PLOS Papers on Malaria in Southeast Asia, Yellow Fever in Brazil, Dengue Virus Genotyping

In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
26
Featured Webinar

Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases

Sponsored by
Bionano Genomics

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics. 

What's Popular?

In Molecular Diagnostics

  1. Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

  2. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  3. Guardant Health Colorectal Cancer Early-Detection Test Progresses Despite Pandemic Challenges

    Premium

  4. Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

    Premium

  5. Wide Variation in Genomic Testing Utilization Across US, Report Finds

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.